Break it Down: LTR Pharma develops new nasal spray for OMD’s

LTR Pharma has joined forces with Strategic Drug Solutions to developed a nasal spray to treat oesophageal motility disorders.

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Tylah Tully looks at news from LTR Pharma (ASX:LTP)  who have signed a collaborative agreement with Strategic Drug Solutions to develop a novel-treatment for oesophageal motility disorders.

Using its patented nasal spray technology to treat erectile dysfunction, LTR has created OROFLOW, a treatment designed to enter the bloodstream quickly for rapid symptom relief avoiding the need to swallow a pill.

Watch the video to hear more.

While LTR Pharma is a Stockhead advertiser, it did not sponsor this content.

Originally published as Break it Down: LTR Pharma develops new nasal spray for OMD’s